DALLAS, March 27, 2015
/PRNewswire/ --
This research says Being bullish about China's demand for human vaccines and exports,
many vaccine producers scale up efforts in vaccine R&D or
expand capacity, such as Walvax Biotechnology.
A vaccine is a preventive biological product for human use that
prevents and controls the occurrence and prevalence of infectious
diseases, so the demand for such products is relatively rigid. Due
to suspected deaths stemming from vaccination and some companies'
(such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products
because of their failure to pass new GMP certification,
China's human vaccine lot release
volume in 2014 declined by 2.4% year on year to 791 million
doses.
Major Chinese Vaccine Producers
China National Biotec Group Co., Ltd., Hualan Biological
Engineering Inc., Chongqing Zhifei Biological Products Co., Ltd.,
Walvax Biotechnology Co., Ltd., Sinovac Biotech Ltd., Liaoning
Chengda Co., Ltd., Changchun BCHT Biotechnology Co. Ltd., Changchun
Changsheng Life Sciences Limited, Zhejiang Tianyuan
Bio-Pharmaceutical Co., Ltd., Shenzhen Kangtai Biological Products
Co. Ltd., Dalian Hissen Bio-pharm
Co., Ltd., NCPC GeneTech Biotechnology Development Co., Ltd.,
Dalian Aleph Biomedical Co., Ltd.
Beijing Minhai Biotechnology Co., Ltd., Shenzhen Sanofi Pasteur
Biological Products Co., Ltd., Jiangsu Simcere Vaxtec
Bio-pharmaceutical Co., Ltd.
Human Vaccine Market Segments in China
Hepatitis B Vaccine, Meningococcal Vaccine, Hepatitis A Vaccine,
Influenza Vaccine, Hib Vaccine, Human Rabies Vaccine, Varicella
Vaccine, Pneumococca Vaccine, DTP Vaccine, Poliomyelitis
Vaccine
Order a copy of this report (China Human Vaccine
Industry Report,
2015-2018) athttp://www.rnrmarketresearch.com/contacts/purchase?rname=329371 .
Affected by China's
less-developed economy, existing national vaccine prevention
policies and people's awareness of epidemic prevention, free EPI
vaccines prevail in China with a
share of about 80% in the total lot release volume. Chinese free
human vaccine market is still dominated by Beijing Tiantan
Biological Products, Chengdu Institute of Biological Products Co.,
Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou
Institute of Biological Products Co., Ltd., Wuhan Institute of
Biological Products Co., Ltd., Changchun Institute of Biological
Products Co., Ltd., Institute of Medical Biology under Chinese
Academy of Medical Sciences and other state-owned enterprises, but
their market shares are falling. In 2014, the EPI vaccine lot
release volume of Chinese state-owned enterprises accounted for
72%, down 6.5 percentage points compared with the previous
year.
However, as China gradually
relaxes control over the vaccine market, private companies and
foreign players are emerging in market segments of extra EPI
vaccine, with their proportions increasing constantly, accounting
for 80% in terms of lot release volume. Moreover, private and
foreign brands hold a dominant position in the markets of
Haemophilus influenza B (Hib), human rabies vaccine, varicella
vaccine, and influenza vaccine, together making up 91.9%, 83.6%,
86.5%, and 69.5% in terms of lot release volume in 2014.
By early 2015, GMP on-site certification had been carried out
for the company's Diphtheria-tetanus-acellular pertussis combined
vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and
DTaP/Hib had made their way into clinical trials; the company is
applying registration for meningococcal polysaccharide vaccine
(Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru,
Thailand, and India.
China Human Vaccine Industry Report,
2015-2018 highlights the
following:
- Operating environment, overall situation, sales channel, etc.
of China human vaccine
industry;
- Supply & demand, competitive landscape, import &
export, and development forecast of the Chinese human vaccine
market;
- Supply & demand, competitive landscape, and market prices
of 10 product segments (including hepatitis B vaccine, influenza
vaccine, rabies vaccine, and pneumococcal vaccine) in China;
- Operation, vaccine business, and development prospects of 16
Chinese human vaccine companies.
Related Report
Chinese human vaccine market is still dominated by Beijing
Tiantan Biological, Chengdu Institute of Biology under Chinese
Academy of Sciences, Shanghai Institute of Biological Products Co.,
Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan
Institute of Biological Products Co., Ltd., Changchun Institute of
Biological Products Co., Ltd., Institute of Medical Biology under
Chinese Academy of Medical Sciences and other state-owned
enterprises; but, their market share is falling. In 2013, the lot
release volume of Chinese state-owned enterprises accounted for
69.9%, down 8.6 percentage points compared with last year; whereas,
the share of private and foreign-funded enterprises jumped by 6
percentage points and 2.6 percentage points over the previous year
respectively.
The improved quality of Chinese vaccines, the increased export
tax rebates (from 13% in 2009 to 15%) and other favorable factors
have prompted China's human
vaccine export volume and value to grow quickly. From January to
June of 2014, the export volume and value amounted to 65.08 tons
and USD15.45 million respectively,
representing the separate increase of 115.6% and 50% over the same
period of last year.
As China's vaccine regulatory
system is recognized by WHO, Chengdu Institute of Biology under
Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan
Biological and other domestic vaccine companies are actively
submitting pre-certification application to WHO in order to further
expand overseas markets. In October
2013, the JE (Japanese encephalitis) vaccines of Chengdu
Institute of Biology under Chinese Academy of Sciences were
pre-certified by WHO at first and included in the procurement list
of the United Nations. WHO inspected the influenza (split virion)
vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be
exported in 2015.
Browse more reports on "Diseases &
treatment" at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment .
About Us:
RnRMarketResearch.com is your single source for all market
research needs. Our database includes 500,000+ market research
reports from over 100+ leading global publishers & in-depth
market research studies of over 5000 micro markets. With
comprehensive information about the publishers and the industries
for which they publish market research reports, we help you in your
purchase decision by mapping your information needs with our huge
collection of reports.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion
Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
Connect with Us:
G+ / Google
Plus:https://plus.google.com/u/0/104156468549256253075/
Twitter:https://twitter.com/RnRMR
Facebook:https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS /
Feeds:http://www.rnrmarketresearch.com/feed